Intra-Cellular Therapies (Intra-Cellular Therapies) Gross Margin %

: 91.86% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Intra-Cellular Therapies's Gross Profit for the three months ended in Dec. 2023 was $120.8 Mil. Intra-Cellular Therapies's Revenue for the three months ended in Dec. 2023 was $131.5 Mil. Therefore, Intra-Cellular Therapies's Gross Margin % for the quarter that ended in Dec. 2023 was 91.86%.

The historical rank and industry rank for Intra-Cellular Therapies's Gross Margin % or its related term are showing as below:

ITCI' s Gross Margin % Range Over the Past 10 Years
Min: 90.17 Med: 91.69 Max: 92.7
Current: 92.7

During the past 12 years, the highest Gross Margin % of Intra-Cellular Therapies was 92.70%. The lowest was 90.17%. And the median was 91.69%.

ITCI's Gross Margin % is ranked better than
98.08% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.83 vs ITCI: 92.70

Intra-Cellular Therapies had a gross margin of 91.86% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Intra-Cellular Therapies was 0.00% per year.

Intra-Cellular Therapies Gross Margin % Historical Data

The historical data trend for Intra-Cellular Therapies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

91.59

90.17

91.79

92.70

Intra-Cellular Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %																92.24	92.87	93.50	92.74	91.86

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intra-Cellular Therapies Gross Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Gross Margin % falls into.

Intra-Cellular Therapies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Intra-Cellular Therapies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	428.4	/	462.175
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(462.175 - 33.745)	/	462.175
	=	92.70 %

Intra-Cellular Therapies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	120.8	/	131.506
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(131.506 - 10.702)	/	131.506
	=	91.86 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Intra-Cellular Therapies (NAS:ITCI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Intra-Cellular Therapies had a gross margin of 91.86% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Intra-Cellular Therapies Gross Margin % Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

ITCI:Mexico 23I:Germany 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Executives

Sharon Mates	director, officer: Chairman, President & CEO	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead	officer: SVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam	officer: Chief Medical Officer	C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann	officer: EVP, Chief Commercial Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline	officer: VP of Finance, CFO & Secretary	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas	director	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi	director, 10 percent owner	P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin	officer: EVP and Chief Medical Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover	officer: VP, Clinical Development	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis	officer: SVP, Chief Scientific Officer	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi	10 percent owner	1311 ORLEANS DRIVE, SUNNYVALE CA 94089